医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT2506, a Proposed Biosimilar of Simponi® (Golimumab)

2019年08月14日 PM09:08
このエントリーをはてなブックマークに追加


 

GUANGZHOU, China

Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2506, a proposed biosimilar of Simponi® (golimumab), to EU-sourced Simponi® in normal healthy volunteers. The clinical study is a randomized, double-blind, two-arm, parallel group study that is expected to enroll approximately 182 healthy volunteers. Each patient will receive a single subcutaneous dose of either BAT2506 or EU-sourced Simponi®.

“Initiating our Phase I clinical trial for BAT2506, our proposed biosimilar for Simponi®, represents the fourth biosimilar that Bio-Thera has advanced into clinical trials,” said Shengfeng Li, CEO, Bio-Thera Solutions. “Bio-Thera is committed to bringing safe and effective biosimilars to patients around the world.”

Bio-Thera Solutions is developing several additional proposed biosimilars, including biosimilar versions of Avastin® and Actemra®/RoActemra®, which are both currently being evaluated in global Phase III clinical trials. Bio-Thera Solutions is also pursuing biosimilar versions of Humira® and Stelara®.

About Bio-Thera Solutions
Bio-Thera Solutions Ltd, a leading biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. A leader in next generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials and has applied for marketing authorization for one candidate. In addition, the company has multiple promising candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases. For more information, please visit www.bio-thera.com/en/ or follow us on Twitter (@bio_thera_sol) and wechat (Bio-Thera).

1 Simponi® is a registered trademark of Janssen Biotech, Inc
2 Avastin® is a registered trademark of Genentech, Inc
3 Actemra® is a registered trademark of Genentech, Inc
4 RoActemra® is a registered trademark of Genentech, Inc
5 Humira® is a registered trademark of Abbvie, Inc
6 Stelara® is a registered trademark of Janssen Biotech, Inc

View source version on businesswire.com: https://www.businesswire.com/news/home/20190814005245/en/

CONTACT

Bio-Thera Solutions, Ltd:

Bert E. Thomas IV +1.410.627.1734

bethomas@bio-thera.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • SETi’s Violeds Technology Solution to Support Delta Variant Spreading Prevention
  • Seoul Viosys Reports Record-High Second Quarter 2021 Results
  • Tiens Group Held an International Health Industry Forum
  • Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
  • Engrail Therapeutics 宣布扩展A轮融资至6400万美元